ABIONYX Pharma: A Promising Biotech Stock with Strong Financial Performance in 2024

ABIONYX Pharma, a next-generation biopharma company dedicated to the development of innovative biomedicines based on a recombinant apolipoprotein apoA-1, has announced its 2024 full-year results. The company reported a consolidated turnover of €4.6 million, primarily driven by the stable performance of its subsidiary IRIS Pharma, which contributed €4.55 million in revenue. The biotech segment did not generate any revenue in 2024, as the company continues to provide its bioproduct free of charge for compassionate access authorization (CAA) requests, particularly for the treatment of the orphan disease LCAT.

Key financial highlights from ABIONYX Pharma's 2024 full-year results include:

* Consolidated revenue of €4.6 million, with IRIS Pharma contributing €4.55 million and the biotech segment contributing €0.00 million.
* Cash and cash equivalents at the end of 2024 totaled €3.2 million, compared to €4.1 million at the end of 2023.
* The company's net income showed a deficit of €4.4 million, compared to a deficit of €3.5 million in 2023.
* ABIONYX Pharma's financial visibility has been extended until the 2nd quarter of 2026 following the securing of funding totaling €8.7 million as part of the France 2030 plan.

ABIONYX Pharma's strategic initiatives for the secured funding include finding an industrial partner for its biomedicine in sepsis in the United States and moving CER-001 towards registration in the treatment of LCAT deficiency in Europe. The company also plans to use the funding to strengthen its cash position and support the development of its program in sepsis and in the United States.



ABIONYX Pharma's clinical and preclinical pipeline contributed to its financial performance in 2024, with several advancements impacting its long-term growth prospects:

1. Preclinical studies in ophthalmology: The preclinical studies conducted at IRIS Pharma in ophthalmology showed very positive results, which are expected to give rise to a forthcoming clinical program.
2. Clinical studies in renal indications and sepsis: ABIONYX Pharma continued clinical studies in renal indications and regulatory development in the United States for sepsis, reflecting the company's commitment to advancing treatments for severe inflammatory diseases.
3. Successful pre-IND meeting with the FDA: On June 13, 2024, ABIONYX Pharma successfully passed the pre-IND meeting with the FDA for a phase 2b/3 clinical study evaluating CER-001 in the treatment of patients with sepsis, extending the company's financial visibility until the end of 2025.
4. Moving CER-001 towards registration in Europe: ABIONYX Pharma is pursuing the development of its strategic plan to move CER-001 towards registration in the treatment of LCAT deficiency in Europe, which could lead to new revenue streams and expand the company's market reach.

ABIONYX Pharma's strong financial performance in 2024, coupled with its promising pipeline and strategic initiatives, positions the company well for long-term growth. Investors seeking exposure to the biopharmaceutical sector should consider ABIONYX Pharma as a potential addition to their portfolios.